Literature DB >> 8080688

Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model.

S P Langdon1, A J Crew, A A Ritchie, M Muir, A Wakeling, J F Smyth, W R Miller.   

Abstract

This paper presents results of the in vitro and in vivo effects of anti-oestrogens on the growth of human ovarian cancer cells. Tamoxifen and the "pure" anti-oestrogens, ICI 164,384 and ICI 182,780, inhibited the oestrogen-stimulated growth of the oestrogen receptor (ER)-positive PE04 and PE01 cell lines grown in culture, the latter two compounds being more potent than tamoxifen. In the absence of 17 beta-oestradiol (E2), tamoxifen, but not the pure anti-oestrogens, produced a small degree of growth stimulation in the PE01 and PE04 lines at concentrations between 10((7) and 10(-9) M. In contrast, growth of the ER-negative PE014 line was unaffected by E2 and all three anti-oestrogens. The effects of tamoxifen and ICI 182,780 on PE04 cells grown as xenografts in nude mice were also studied. Both anti-oestrogens produce significant growth inhibitory effects. These results indicate that ovarian carcinoma cells may be sensitive to anti-oestrogens in vitro and in vivo, and support the view that anti-oestrogens merit further clinical studies in patients with ER-positive tumours.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8080688     DOI: 10.1016/0959-8049(94)90545-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  16 in total

1.  MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.

Authors:  Karina E Hew; Philip C Miller; Dorraya El-Ashry; Jun Sun; Alexandra H Besser; Tan A Ince; Mengnan Gu; Zhi Wei; Gao Zhang; Patricia Brafford; Wei Gao; Yiling Lu; Gordon B Mills; Joyce M Slingerland; Fiona Simpkins
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

2.  Impact of post-operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy.

Authors:  Li Li; Zhongmian Pan; Kun Gao; Wei Zhang; Yuan Luo; Zhongqiang Yao; Xinqiang Liang; Bujian Tang; Qingdi Quentin Li
Journal:  Oncol Lett       Date:  2011-10-25       Impact factor: 2.967

3.  Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine epithelium.

Authors:  P S Cooke; D L Buchanan; P Young; T Setiawan; J Brody; K S Korach; J Taylor; D B Lubahn; G R Cunha
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

4.  Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.

Authors:  Fiona Simpkins; Pedro Hevia-Paez; Jun Sun; Wendy Ullmer; Candace A Gilbert; Thiago da Silva; Ali Pedram; Ellis R Levin; Isildinha M Reis; Brian Rabinovich; Diana Azzam; Xiang-Xi Xu; Tan A Ince; Ji-Yeon Yang; Roel G W Verhaak; Yiling Lu; Gordon B Mills; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

5.  Aromatase excess in cancers of breast, endometrium and ovary.

Authors:  Serdar E Bulun; Dong Chen; Meiling Lu; Hong Zhao; Youhong Cheng; Masashi Demura; Bertan Yilmaz; Regina Martin; Hiroki Utsunomiya; Steven Thung; Emily Su; Erica Marsh; Amy Hakim; Ping Yin; Hiroshi Ishikawa; Sanober Amin; Gonca Imir; Bilgin Gurates; Erkut Attar; Scott Reierstad; Joy Innes; Zhihong Lin
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

Review 6.  New insights on the role of hormonal therapy in ovarian cancer.

Authors:  Fiona Simpkins; Arlene Garcia-Soto; Joyce Slingerland
Journal:  Steroids       Date:  2013-02-08       Impact factor: 2.668

7.  Expression Profiles of Estrogen-Regulated MicroRNAs in Cancer Cells.

Authors:  Amena Archer; Claudia Kutter; Cecilia Williams
Journal:  Methods Mol Biol       Date:  2022

8.  Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance.

Authors:  C Palmieri; O Gojis; B Rudraraju; C Stamp-Vincent; D Wilson; S Langdon; C Gourley; D Faratian
Journal:  Br J Cancer       Date:  2013-05-07       Impact factor: 7.640

9.  Local estrogen metabolism in epithelial ovarian cancer suggests novel targets for therapy.

Authors:  Xia Ren; Xuan Wu; Stephen G Hillier; K Scott Fegan; Hilary O D Critchley; J Ian Mason; Sana Sarvi; Christopher R Harlow
Journal:  J Steroid Biochem Mol Biol       Date:  2015-03-24       Impact factor: 4.292

10.  Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer.

Authors:  J Hasan; N Ton; S Mullamitha; A Clamp; A McNeilly; E Marshall; G C Jayson
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.